Case number 1:19-cv-01492
Boehringer Ingelheim Pharmaceuticals Inc. et al v. Aizant Drug Research Solutions Pvt. Ltd. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 25, 2021 | N/A | Terminated Case (0) Docket Text: CASE CLOSED per the entry of the Consent Judgment in Lead Case No. 18-1689-CFC. (nmf) |
| Sep 11, 2019 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:18-cv-01689-CFC-SRF. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 18-1689-CFC ONLY. (nmf) |
| Sep 11, 2019 | 10 | SO ORDERED (12) Docket Text: SO ORDERED, re (83 in 1:18-cv-01689-CFC-SRF, 9 in 1:19-cv-01499-CFC, 8 in 1:19-cv-01498-CFC, 8 in 1:19-cv-01494-CFC, 7 in 1:19-cv-01492-CFC, 8 in 1:19-cv-01495-CFC, 8 in 1:19-cv-01501-CFC, 8 in 1:19-cv-01596-CFC, 9 in 1:19-cv-01500-CFC, 9 in 1:19-cv-01493-CFC, 8 in 1:19-cv-01594-CFC, 8 in 1:19-cv-01497-CFC, 7 in 1:19-cv-01496-CFC) STIPULATION Stipulation and [Proposed] Order for Consolidation. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 18-1689-CFC. Plaintiffs and Defendants shall follow the Scheduling Order entered in the Consolidated Action except for those deadlines outlined in this order. Signed by Judge Colm F. Connolly on 9/9/2019. Associated Cases: 1:18-cv-01689-CFC-SRF et al.(nmf) |
| Sep 11, 2019 | 11 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aizant Drug Research Solutions Pvt. Ltd.s Initial Disclosures Pursuant to Rule 26(a)(1) and Aizant Drug Research Solutions Pvt. Ltd.s Initial ESI Disclosures filed by Aizant Drug Research Solutions Pvt. Ltd..(Stamoulis, Stamatios) |
| Sep 4, 2019 | 8 | Answer to Complaint (17) Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against All Plaintiffs by Aizant Drug Research Solutions Pvt. Ltd..(Stamoulis, Stamatios) |
| Sep 4, 2019 | 9 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Aizant Drug Research Solutions Pvt. Ltd.. (Stamoulis, Stamatios) |
| Aug 30, 2019 | 7 | Stipulation (12) Docket Text: STIPULATION Stipulation and [Proposed] Order for Consolidation by Cipla Limited, Cipla USA, Inc., Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., MSN Laboratories Private Ltd., MSN Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Sun Pharmaceutical Industries, Inc., Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc.. (Phillips, John) |
| Aug 14, 2019 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:19-cv-01492-CFC et al.(nmg) |
| Aug 14, 2019 | 6 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH. Aizant Drug Research Solutions Pvt. Ltd. served on 8/14/2019, answer due 9/4/2019. (Dellinger, Megan) |
| Aug 9, 2019 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Aizant Drug Research Solutions Pvt. Ltd. on 8/9/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (kmd) |
| Aug 9, 2019 | 1 | Exhibit 1 (48) |
| Aug 9, 2019 | 1 | Civil Cover Sheet (1) |
| Aug 9, 2019 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (kmd) |
| Aug 9, 2019 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 6/24/2019. Date of Expiration of Patent: 4/3/2034.Thirty Month Stay Deadline: 2/1/2022. (kmd) |
| Aug 9, 2019 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,258,637 B2. (kmd) |
| Aug 9, 2019 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG. for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. (kmd) |
| Aug 9, 2019 | 1 | Complaint* (1) |
